Galderma has announced new clinical data showing the effectiveness of a promising new combination treatment for the skin disease rosacea.
Published in the Journal of Drugs in Dermatology, the study assessed the performance of the combined use of the topical rosacea treatments ivermectin one percent cream and brimonidine 0.33 percent gel.
“Galderma has reported new clinical data demonstrating the benefits of a combined topical rosacea treatment.“
It was shown that the combination was able to effectively target the multiple features of rosacea, which include flushing, permanent erythema and inflammatory lesions.
Gregor Schaefer, medical lead at Galderma, said: "The visible signs of rosacea can significantly impact patients' quality of life. Galderma is committed to supporting patients through the development of practical treatment options."
Rosacea is a common inflammatory skin disease that mainly affects the central areas of the face, such as the cheeks and nose. It can affect both adult men and women, usually over the age of 30, and can be triggered by factors such as spicy foods, alcohol, emotional stress, sun exposure, hot baths and certain beverages.
With over 20 years of experience within the consumer market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current consumer roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Consumer